Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

Treatment for Bacillus Calmette-Guérin (BCG)- Unresponsive Non-Muscle Invasive Bladder Cancer Webinar

September 25, 2025 | 3:30 p.m. ET

This presentation on INLEXZO™, (gemcitabine intravesical system) will focus on efficacy, safety information, and procedural education.

Christopher M. Pieczonka, MD

Christopher M. Pieczonka, MD

Corporate Director of Clinical Research, U.S. Urology Partners
Chief Executive Officer, Associated Medical Professionals of NY

Dr. Christopher Pieczonka graduated from the SUNY Buffalo School of Medicine in 1997. He then completed his surgical and urologic training at SUNY at Buffalo Consortium Program in 2003. He is board certified by the American Board of Urology and is an active member of the American Urological Association (AUA); American Society of Clinical Oncology (ASCO); and the Society of Urologic Oncology (SUO). Dr. Pieczonka also has been co-author of over 100 publications and published abstracts.

This is a non-CME, company-led program developed and sponsored by Johnson & Johnson, intended for healthcare professionals only. The content of this company-directed program is not sponsored or endorsed by the American Urological Association (AUA).